PHARMA LITERATI

Who can attend ?  Teachers and research scholars (PG and PhD) in the faculty of Pharmaceutical Sciences, Basic Sciences, and Life Sciences.  Objectives of the Programme: Sensitize the teachers and research scholars (PG and PhD) to the importance of pharmaceutical analysis in industry.   Exposure to current concepts in pharmaceutical analysis like Quality by design, proteomics and biosimilars, recent trends in analysis of pharmaceuticals, radiopharmaceuticals and herbal products, stability sample management, pharmacopoeial testing, regulatory compliance and data integrity .   Understand the intricacies involved in development and validation of an analytical procedure.   Discuss case studies related to analytical method development.  Networking and understanding the regulatory requirements of industry.  Distinguished Speakers: Dr. Trupti Tol , Cipla Ltd.   Dr. Sasikumar Menon, Therapeutic Drug Monitoring Laboratory  Dr. Shreerang Joshi , Professor, Institute

New research has found that Cannnabidiol is active against Gram-positive bacteria, including those responsible for many serious infections (such as Staphyloccocus aureus and Streptococcus pneumoniae), with potency similar to that of established antibiotics such as vancomycin or daptomycin. The research is presented at ASM Microbe, the annual meeting of the American Society for Microbiology. Cannabidiol, the main non-psychoactive chemical compound extracted from cannabis and hemp plants, has been approved by FDA for the treatment of a form of epilepsy, and is being investigated for a number of other medical conditions, including, anxiety, pain and inflammation. While there is limited data to suggest Cannabidiol can kill bacteria, the drug has not been thoroughly investigated for its potential as an antibiotic. Work led by Dr Mark Blaskovich at The University of Queensland’s Institute for Molecular Bioscience’s Centre for Superbug Solutions, in collaboration with Botanix Pharm

Nandita Vijay, Bengaluru Friday, June 21, 2019, 08:00 Hrs  [IST] Herbaceuticals is a science with a holistic approach to integrate modern medicine with an evidence-based identity, said Dr. V Prakash, distinguished scientist, CSIR-India and former director, CFTRI, Mysore. There is considerable importance on the science of Herbaceuticals for the Indian pharma industry. In an age of integrated healthcare where Ayush therapies are being accepted along with the modern medicine, we see that these are separate compartments in theory and practice. However, there is an increasing need to combine modern and traditional medicine, he added. In his recently launched book titled Herbaceuticals, Dr. Prakash along with his co-editor Dr. DBA Narayana, expert member, Indian Pharmacopoeia Commission, stated that it was important to highlight the indispensability of Herbaceuticals which is also referred to as nutraceuticals and Ayushceuticals. “This book published by IFFRIFANS and Ayurvidye Trust of

Sanofi and Google will establish a new virtual Innovation Lab with the ambition to radically transform how future medicines and health services are delivered by tapping into the power of emerging data technologies. “We stand on the forefront of a new age for biology and human health, with the opportunity to transform healthcare through partnerships with pioneering technology and analytics companies,” says Ameet Nathwani, M.D., chief digital officer, chief medical officer & executive vice president, Medical at Sanofi. “Combining Sanofi’s biologic innovations and scientific data with Google’s industry-leading capabilities, from cloud computing to state-of-the-art artificial intelligence, we aspire to give people more control over their health and accelerate the discovery of new therapies.” The collaboration aims to change how Sanofi develops new treatments and will focus on three key objectives: to better understand patients and diseases, to increase Sanofi’s operational efficien

Maryland Tuesday, June 18, 2019, 12:00 Hrs  [IST] National Institutes of Health (NIH) scientists have used human skin cells to create what they believe is the first cerebral organoid system, or “mini-brain,” for studying sporadic Creutzfeldt- Jakob disease (CJD). CJD is a fatal neurodegenerative brain disease of humans believed to be caused by infectious prion protein. It affects about 1 in 1 million people. The researchers, from NIH’s National Institute of Allergy and Infectious Diseases (NIAID), hope the human organoid model will enable them to evaluate potential therapeutics for CJD and provide greater detail about human prion disease subtypes than the rodent and nonhuman primate models currently in use. Human cerebral organoids are small balls of human brain cells ranging in size from a poppy seed to a small pea. Their organization, structure, and electrical signaling are similar to brain tissue. Because these cerebral organoids can survive in a controlled environment for mont

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Polivy™ (polatuzumab vedotin-piiq) in combination with bendamustine plus Rituxan® (rituximab) (BR) for the treatment of adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who have received at least two prior therapies. Accelerated approval was granted for this indication based on complete response rates observed in a randomised, controlled clinical trial. The FDA's Accelerated Approval Program allows conditional approval of a medicine that fills an unmet medical need for a serious condition. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. "Despite meaningful progress in the treatment of diffuse large B-cell lymphoma, treatment options are very limited when the disease is refractory to or recurrent after multiple regimens," said

The interim analysis revealed that over 71 percent of patients treated with Ilumya experienced a 20 percent improvement in joint and skin symptoms, meeting the primary endpoint of the study, Sun Pharma said in a statement. Moneycontrol News. Sun Pharma  on June 14 announced promising interim results from a Phase 2 study on Ilumya, a drug used to treat active psoriatic arthritis in patients. The announcement was made at the Annual European Congress of Rheumatology in Madrid, Spain. Ilumya is already approved in the US for the treatment of adults with moderate-to-severe plaque psoriasis and is now being investigated for psoriatic arthritis. The positive results for additional indication can help Sun Pharma to expand its sales of the drug. Ilumya, generically called as tildrakizumab-asmn, belongs to the class of interle

Source: Pharmaprojects; Credit: Informa UK.

SKB College of Pharmacy, Kamptee will be organising an AICTE Sponsored  Two-week National Level Faculty Development Program entitled  "ICT-blended Teaching-Learning"  from 1st - 13th July 2019.  Website: www.skb.edu.in

Pharma Literati Centre of Excellence in Pharma Education is pleased to announce the new batches of the Courses. We are launching the course on Regulatory Affairs from this year. Register at: Courses:   https://docs.google.com/forms/ d/19hhXRM_S_Ka92G_ mGVjdiP6OZgt8EYxvxrwe2jI-LuM/ viewform?edit_requested=true GPAT:  https://docs.google.com/ forms/d/ 1kcugij2VLZjDK64f7DXky0N6wWsdI 9P8L9BmVx1AO6w/edit?usp=forms_ home&ths=true From this year, we are providing free registration for economically backward students. To know more, kindly send an email to pharmaliterati@gmail.com

Silver Spring, Maryland Wednesday, June 5, 2019, 14:00 Hrs  [IST] The US Food and Drug Administration (FDA) approved a new indication for the previously FDA-approved drug, Zerbaxa (ceftolozane and tazobactam) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients 18 years and older. The FDA initially approved Zerbaxa in 2014 to treat complicated intra-abdominal infections and for complicated urinary tract infections. "A key global challenge we face as a public health agency is addressing the threat of antimicrobial-resistant infections," said FDA Principal Deputy Commissioner Amy Abernethy, M.D., Ph.D. "Hospital-acquired and ventilator-associated bacterial pneumonia are serious infections that can result in death in some patients. New therapies to treat these infections are important to meet patient needs because of increasing antimicrobial resistance. That's why, among our other efforts t

After decades of ground-breaking laboratory works, the world’s scientific and technical community, in a landmark and historic decision taken in the recent open session of the General Conference on Weights and Measures (CGPM) at BIPM on 16 November 2018, has unanimously adopted the resolution to redefine four of the seven base units, the kilogram (SI unit of weight), Kelvin (SI unit of temperature), mole (SI unit of amount of substance), and ampere (SI unit of current). This decision has now enabled scientists and researchers to base the SI units entirely on fundamental properties of nature, which will ensure their ongoing refinement and improvement for years to come. The fundamental constants are invariants of time and space and successfully replaced the artifact based units, and aptly opened up the new era for quantum world by linking all seven base units to fundamental constants/quantum standards. The new SI is being implemented worldwide from 20th May 2019 i.e. the World Metro